Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.
Type:
Grant
Filed:
February 15, 2017
Date of Patent:
January 22, 2019
Assignee:
Celldex Therapeutics, Inc.
Inventors:
Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
Abstract: The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
Type:
Grant
Filed:
April 30, 2015
Date of Patent:
January 15, 2019
Assignee:
GENENTECH, INC.
Inventors:
Robert F Kelley, Menno van Lookeren Campagne, Justin M Scheer, Philip E Hass, Devin Tesar
Abstract: The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.
Type:
Grant
Filed:
October 31, 2017
Date of Patent:
January 8, 2019
Inventors:
Li-Te Chin, Shu-Ching Hsu, Kai-Chen Wang
Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
Type:
Grant
Filed:
May 27, 2016
Date of Patent:
January 8, 2019
Assignee:
ABBVIE, INC.
Inventors:
Lorenzo Benatuil, Bradford L. McRae, Chung-Ming Hsieh, Rui Wang
Abstract: A pharmaceutical composition includes an isolated anti-Bb antibody or antigen binding portion thereof produced by a hybridoma cell line deposited under ATCC Accession Number PTA-8543 or an isolated anti-Bb antibody or antigen binding portion thereof that competitively inhibits binding of the antibody or antigen binding portion produced by the hybridoma cell line deposited under ATCC Accession Number PTA-8543 to the Bb segment of factor B; and a pharmaceutically acceptable carrier.
Abstract: The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
Abstract: Anti-CD40 antibodies are formulated as lyophilizate or liquid formulation. The lyophilizates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilizate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilizate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
Type:
Grant
Filed:
August 2, 2017
Date of Patent:
October 23, 2018
Assignee:
ALS Therapy Development Institute
Inventors:
John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.
Type:
Grant
Filed:
October 23, 2017
Date of Patent:
October 9, 2018
Assignee:
Allergan, Inc.
Inventors:
Yanbin Liang, Chen Li, Iris Lee, Victor M. Guzman
Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
Type:
Grant
Filed:
January 9, 2017
Date of Patent:
October 2, 2018
Assignee:
Baylor Research Institute
Inventors:
Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
Abstract: This disclosure relates to specific binding agents, such as isolated recombinant monoclonal antibodies, that bind Glycoprotein Ib alpha (GPIba). More specifically, the disclosure relates to methods of preventing platelet ectodomain shedding, preventing platelet clearance and degradation, maintaining and increasing platelet blood serum levels for in vitro or in vivo applications. In some embodiments, the disclosure relates to the production, diagnostic use, and therapeutic use of monoclonal and polyclonal antibodies, and the antigen-binding fragments thereof, which specifically bind GPIba. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies for specific binding agent. Compositions and methods for inhibiting shedding, clearance, or degradation, or treating diseases associated with GPIba ectodomain shedding are also described.
Type:
Grant
Filed:
February 3, 2014
Date of Patent:
September 25, 2018
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.
Type:
Grant
Filed:
April 24, 2013
Date of Patent:
August 7, 2018
Assignee:
OXFORD UNIVERSITY INNOVATION LIMITED
Inventors:
Daniel Clive Anthony, Sandra Jane Campbell, Francis Joseph Carr, Robin Patrick Choudhury, Benjamin Guy Davis, Timothy David Jones, Nicola Ruth Sibson
Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
Type:
Grant
Filed:
March 15, 2017
Date of Patent:
July 24, 2018
Assignee:
AbGenomics Cooperatief U.A.
Inventors:
Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Type:
Grant
Filed:
February 21, 2018
Date of Patent:
July 17, 2018
Assignee:
AbbVie Biotherapeutics Inc.
Inventors:
Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.
Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
Type:
Grant
Filed:
October 10, 2012
Date of Patent:
June 19, 2018
Assignee:
Viela Bio, Inc.
Inventors:
Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
Type:
Grant
Filed:
June 19, 2014
Date of Patent:
June 5, 2018
Assignee:
NOVARTIS AG
Inventors:
Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
Type:
Grant
Filed:
March 12, 2012
Date of Patent:
June 5, 2018
Assignees:
Beth Israel Deaconess Medical Center, Inc., Emory University
Inventors:
Keith A. Reimann, Rijian Wang, Christian P. Larsen
Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.